Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo
New data with AstraZeneca’s oral Factor D inhibitor danicopan have built the case for the drug as an add-on to complement C5 antibodies for the treatment of paroxysmal noc
Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o
The final day of the ASH congress always includes a session on late-breaking studies, and this year was no exception, with presentations on Novartis' iptacopan in paroxysmal nocturnal haemo
As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n